Tego Science테고사이언스
191420 · KOSDAQ · ₩191420 · 테고사이언스
- Market cap
- ₩57B
- Enterprise value
- ₩15B
- P/E
- —
- P/B
- 1.3×
- Dividend yield
- 0.0%
- ROE
- −29.6%
- Net margin
- −208.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−61.9% from the high
₩5,230Today: ₩6,900 – ₩7,260₩18,500
Returns
- 1W+1.7%
- 1M−3.3%
- 3M+12.1%
- 6M−43.5%
- YTD−56.8%
- 1Y−60.0%
- Volume today
- 1,156
- 0.3× the 20-day average
- Traded today
- ₩8.1M
- Listed shares
- 8,108,834
- EPS (12 months)
- −₩1,593
- Earnings yield −22.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 28 of 100 (50 is a normal day for this stock).
- MomentumFlat-2.5% over the last month; the price is above its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Tego Science stock overview
Tego Science (테고사이언스, KRX: 191420) is listed on KOSDAQ, in the Biotech & Pharma sector. Tego Science Inc. Its shares closed at ₩7,040 on Oct 30, 2026, down 3.03% on the day, giving it a market value of ₩57B.
Key facts
- Market cap
- ₩57B
- Sector
- Biotech & Pharma
- Latest price change
- −3.03%
- As of
- Oct 30, 2026
- Main business
- Tego Science Inc.
Quick answers about Tego Science
- What does Tego Science do?
- Tego Science Inc. is a Korean company that develops and manufactures cell therapy products based on cell culture technology, offering development consulting, contract manufacturing, and quality control services. It also sells three-dimensional cultured skin models used for animal-alternative testing and performs contract research with them.
- What is the market cap of Tego Science?
- The market capitalisation of Tego Science was ₩57B at the close on Oct 30, 2026.
- Who are the largest shareholders of Tego Science?
- According to the latest official filings, the largest reported holders are Jeon Se-hwa (41.79%, as of Sep 22, 2026); Jeon Jae-wook (6.70%, as of Sep 22, 2026); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.00%, as of Jul 31, 2026).
- When is the next earnings report from Tego Science?
- Korean companies rarely announce results dates in advance. Based on when Tego Science filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Tego Science Inc. is a Korean company that develops and manufactures cell therapy products based on cell culture technology, offering development consulting, contract manufacturing, and quality control services. It also sells three-dimensional cultured skin models used for animal-alternative testing and performs contract research with them. Its main cell therapy products are used for burn and diabetic foot ulcer treatment and wrinkle improvement, and it sells to hospitals through its sales division and distributors in Korea, with the company also pursuing contract development and manufacturing (CDMO) work for other developers.
Written by AI from the company's latest annual report.
- Korean name
- 테고사이언스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 전세화
- Founded
- Mar 2001
- Listed
- Nov 2014
- Listed shares
- 8,108,834
- Fiscal year ends
- Month 12
- Website
- www.tegoscience.com
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent filings
See all- Insider shareholding reportSep 22, 2026
- 5%+ holding reportSep 22, 2026
- Trading Plan Report for Executives and Major Shareholders' Specific SecuritiesAug 18, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Amended: Annual report (Dec 2025)Jun 25, 2026
Titles in Korean until English translations are added.
Also known as: Tego Science / 테고사이언스 / 191420 / KRX:191420
Source: KRX statistical information